Parkwalk Advisors
VC Fund
London, United Kingdom
Parkwalk Advisors is a VC fund in London focused on Biotechnology and Health Care. Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
- Total investments:
- 290
- Last investment:
- Lead investor:
- 28%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Parkwalk Advisors invests in
Stages Parkwalk Advisors invests in
Countries Parkwalk Advisors invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.2M–$4.8M
- Series A
- $1.6M–$15M
- Series B
- $2M–$45M
Investment Focus
Industry
- Biotechnology 33 (11%)
- Health Care 28 (10%)
- Software 27 (9%)
- Information Technology 21 (7%)
- Medical 16 (6%)
Stage
- Seed 67 (23%)
- Series A 55 (19%)
- Series B 29 (10%)
- Funding Round 23 (8%)
- Series C 10 (3%)
Country
- United Kingdom 122 (42%)
- United States 2 (1%)
- Philippines 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alastair Kilgour
Co-Founder and Partner
|
Co-Founder and Partner | Total investments: 44 | Find email | |
Alun Williams
Investment Director
|
Investment Director | Total investments: 17 | Find email | |
Chloe Richardson
Investor Relations Manager
|
Investor Relations Manager | Total investments: 1 | Find email | |
Douglas Wright
CEO and Co-Founder
|
CEO and Co-Founder | Total investments: 20 | Find email | |
Enrico D'Angelo
Finance Director
|
Finance Director | Total investments: 0 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MoA Technology
|
MoA Technology Limited is a plant genetics company spun out from the University of Oxford. Professor Liam Dolan, FRS, has developed an innovative approach for the discovery of agricultural technologies that will enable farmers to produce healthy food from sustainable crop systems. | $29.7M / Series C / Jul 23, 2026 | |
K3 Metrology
|
K3 Metrology is a specialist metrology company commercialising laser‑based 3D coordinate measurement technology developed at the National Physical Laboratory. The company’s platform is designed to provide high‑accuracy, uncertainty‑aware dimensional data in large‑volume industrial environments, supporting inspection and assembly processes inadvanced manufacturing. Its systems integrate into production workflows where traceable measurements are required across complex geometries and large structures. The technology is applied in sectors such as aerospace, defence, and nuclear, where dimensional integrity and process control are critical. | $3.7M / Seed / May 14, 2026 | |
Quantum Motion
|
Quantum Motion Technologies is building a universal quantum computer in Silicon, using CMOS compatible processes. | $163.5M / Series C / May 07, 2026 | |
Semarion
|
Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. Semarion combines microchip industry materials and techniques engineering and cell biology to tackle unmet drug screening needs. | $3.8M / Venture - Series Unknown / Mar 31, 2026 | |
Brainomix
|
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $6.5M / Series C / Feb 24, 2026 | |
|
Brainomix
|
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. | $6.5M / Series C / Feb 24, 2026 | |
xWatts
|
xwatts is an intelligent energy management system that helps commercial buildings reduce costs and emissions. | $2.2M / Seed / Feb 10, 2026 | |
Scripta Therapeutics
|
Scripta Therapeutics operates as a bio-tech company, that delivers transformative therapeutics through cutting edge technology. | $12M / Seed / Nov 13, 2025 | |
NoBACZ
|
NoBACZ is pioneering a novel, new precision bandaging platform for the veterinary and human market. The company specializes in rapid set liquid barriers. | $6.4M / Sep 29, 2025 | |
Trismik
|
Trismik is building an adaptive evaluation platform that tests LLMs for real-world risks such as hallucinations, bias, and factual inaccuracies. | $3M / Pre-Seed / Sep 24, 2025 | |
| See all 290 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Parkwalk Advisors invest in?
Parkwalk Advisors invests primarily in Biotechnology, Health Care and Software startups, most often at Seed and Series A stage. Most of the 290 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Parkwalk Advisors's check size?
Parkwalk Advisors typically joins rounds of $1.2M–$4.8M at Seed, $1.6M–$15M at Series A and $2M–$45M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Parkwalk Advisors participates in.
How do I contact Parkwalk Advisors?
Public channels for Parkwalk Advisors include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Parkwalk Advisors?
The team at Parkwalk Advisors includes Alastair Kilgour (Co-Founder and Partner), Alun Williams (Investment Director) and Chloe Richardson (Investor Relations Manager), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
